Asset profile
SAR441566
Small molecule
Evidence outlook · lead readout
NCT06073093 · Rheumatoid Arthritis
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06073093: The study randomized 264 participants to four SAR441566 dose regimens or placebo and used triple masking of participants, investigators, and outcome assessors. Its primary endpoint was the clinical ACR20 response at week 12, but results have not been posted, so whether the endpoint was met or missed cannot be assessed.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (2)
July 2027 (2)
What to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchWhat to watch
Research analysis
Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.
Sign in to access ResearchAll registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.